Semaglutide ameliorates coronary microembolization-induced injury by suppressing apoptosis and inflammation via the HMGB1/RAGE/NF-κB p65 pathway
{{output}}
Background: Coronary microembolization (CME) is the major leading cause of perioperative myocardial injury during coronary revascularization. Semaglutide exerts multiple protective biological activities, but its cardioprotective ... ...
